Alligator Bioscience AB: Interim report January–June 2021
Positive Phase I data for ATOR-1017 ”As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on ...
Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical data
Lund, Sweden, June 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Nasdaq Stockholm: SCOL) today announces ...
Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy
Lund, Sweden, June 7, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the scientific journal Expert Opinion on Bi ...
Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017
Lund, Sweden, June 4, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today presents novel supportive data from the ongoing Phase I cl ...
Bulletin from the annual general meeting in Alligator Bioscience AB on June 1, 2021
Lund, Sweden, June 1, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the annual general meeting was held in the ...
Alligator’s mitazalimab shown to enhance cancer vaccine
Lund, Sweden, May 5, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that preclinical data on its agonist anti-CD40 an ...
Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field
Lund, Sweden, May 4, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research agreeme ...
Board member in Alligator Bioscience resigns at his own request
Lund, Sweden, April 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company's Board member Carl Borre ...
Alligator Bioscience AB: Interim report January–March 2021
High activity during the first quarter ”So far, 2021 has been characterized by high activity, with a research collaboration that validates o ...